Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes

[1]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[2]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[3]  V. Hasselblad,et al.  Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. , 2004, JAMA.

[4]  J. Gore,et al.  Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study , 2004, Annals of Internal Medicine.

[5]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[6]  Werner Klein,et al.  Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes , 2002 .

[7]  R. Califf,et al.  The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. , 2001, American heart journal.

[8]  R. Califf,et al.  Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.

[9]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[10]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[11]  M. Mercuri,et al.  Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[12]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.